참고문헌
- Bertsch T, Aschenneller C, Bewarder N, et al (2013). European proficiency study with control serum for the tumor marker CA19-9 measured on different test system. Clin Lab, 59, 185-92.
- Duraker N, Hot S, Polat Y, et al (2007). CEA, CA19-9, and CA125 in the differential diagnosis of benign and malignant pancreatic diseases with or without jaundice. J Surg Oncol, 95, 142-7. https://doi.org/10.1002/jso.20604
- Frucht H, Stevens PD, Fogelman DR, et al (2004). Advances in the Genetic Screening, Work-up, and Treatment of Pancreatic Cancer. Curr Treat Options Gastroenterol, 7, 343-54. https://doi.org/10.1007/s11938-004-0047-8
- He Y, Zheng R, Li D, et al (2015). Pancreatic cancer incidence and mortality patterns in China, 2011. Chin J Cancer Res, 27, 29-37.
- Humphris JL, Chang DK, Johns AL, et al (2012). The prognostic and predictive value of serum CA19-9 in pancreatic cancer. Ann Oncol, 23, 1713-22. https://doi.org/10.1093/annonc/mdr561
- Jamieson NB, Carter CR, Mckay CJ, et al (2011). Tissue biomarkers for prognosis in pancreatic ductal adenocarcinoma: a systematic review and meta-analysis. Clin Cancer Res, 17, 3316-31. https://doi.org/10.1158/1078-0432.CCR-10-3284
- Jemal A, Siegel R, Ward E, et al (2008). Cancer statistics. CA Cancer J Clin, 58, 71-96. https://doi.org/10.3322/CA.2007.0010
- Jiang XT, Tao HQ, Zou SC (2004). Detection of serum tumor markers in the diagnosis and treatment of patients with pancreatic cancer. Hepatobiliary Pancreat Dis Int, 3, 464-8.
- Li XY, Guo XZ, Li HY, et al (2014). Application of tumor markers in diagnosis and prognosis assessment of pancreatic cancinoma. Chin J Prac Int Med, 34, 499-503.
- Lin QJ, Yang F, Jin C, et al (2015). Current status and progress of pancreatic cancer in China. World J Gastroenterol, 21, 7988-8003.
- Liu F, Du F1, Chen X (2014). Multiple tumor marker protein chip detection system in diagnosis of pancreatic cancer. World J Surg Oncol, 12, 333. https://doi.org/10.1186/1477-7819-12-333
- Mu XF, Cao JX, Wang YX, et al (2011). Clinical value of serum CA19-9, CEA and CA125 in diagnosis and prognosis of unresectable pancreatic cancer patients treated with chemotherapy. Clin Focus, 26, 113-6.
- Reitz D, Gerger A, Seidel J, et al (2015). Combination of tumour markers CEA and CA19-9 improves the prognostic prediction in patients with pancreatic cancer. J Clin Pathol, 68, 427-33. https://doi.org/10.1136/jclinpath-2014-202451
- Wu AZ, Liang Z, Wang HF (2011). Analysis of serum CA19-9, CA242, CA125 and CEA of pancreatic cancer patients. Chin J Lab Diagn, 15, 1087-8.
- Zhou G, Niu L, Chiu D, et al (2012). Changes in the expression of serum markers CA242, CA19-9, CEA, TNF x03b1, and TSGF after eryosurgery in pancreatic cancer patients. Biotechnol Lett, 34, 1235-41. https://doi.org/10.1007/s10529-012-0908-5
피인용 문헌
- Clinical value of preoperative serum CA 19-9 and CA 125 levels in predicting the resectability of hilar cholangiocarcinoma vol.5, pp.1, 2016, https://doi.org/10.1186/s40064-016-2181-x
- Potential Biomarkers in Lewis Negative Patients With Pancreatic Cancer vol.265, pp.4, 2017, https://doi.org/10.1097/SLA.0000000000001741
- Novel Diagnostic and Predictive Biomarkers in Pancreatic Adenocarcinoma vol.18, pp.3, 2017, https://doi.org/10.3390/ijms18030667
- Diagnostic Value of CA 19-9 and Carcinoembryonic Antigen for Pancreatic Cancer: A Meta-Analysis vol.2018, pp.1687-630X, 2018, https://doi.org/10.1155/2018/8704751
- Pretreatment values of bilirubin and albumin are not prognostic predictors in patients with advanced pancreatic cancer pp.20457634, 2018, https://doi.org/10.1002/cam4.1848
- RETRACTED ARTICLE: Pre-treatment DWI as a predictor of overall survival in locally advanced pancreatic cancer treated with Cyberknife radiotherapy and sequential S-1 therapy vol.18, pp.1, 2018, https://doi.org/10.1186/s40644-018-0139-7
- Combined pretreatment serum CA19-9 and neutrophil-to-lymphocyte ratio as a potential prognostic factor in metastatic pancreatic cancer patients vol.97, pp.4, 2018, https://doi.org/10.1097/MD.0000000000009707
- Proteomic and genomic profiling of pancreatic cancer pp.1573-6822, 2019, https://doi.org/10.1007/s10565-019-09465-9